The first phase III, prospective, randomized, multicenter trial to evaluate its efficacy and safety for HER2-positive GC treatment was the Trastuzumab for Gastric Cancer (ToGA) study (7–9). This evidence concerns the gene ERBB2 and gastric cancer.